{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:59:51Z","timestamp":1793289591931,"version":"4.5.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Sarcopenia and inflammation are independently associated with worse survival in cancer patients. This study aims to determine the impact of sarcopenia, body mass index (BMI), and inflammatory biomarkers on survival in advanced hepatocellular carcinoma (HCC) patients treated with anti-PD-1 antibody-based immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective review of advanced HCC patients treated with immunotherapy at Winship Cancer Institute between 2015 and 2019 was performed. Baseline computed tomography and magnetic resonance images were collected at mid-L3 level, assessed for skeletal muscle density using SliceOmatic (TomoVision, version 5.0) and converted to skeletal muscle index (SMI) by dividing it by height (m<jats:sup>2<\/jats:sup>). Sex-specific sarcopenia was defined by the median value of SMI. The optimal cut for continuous inflammation biomarker was determined by bias-adjusted log-rank test. Overall survival (OS) was set as primary outcome and Cox proportional hazard model was used for association with survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 57 patients were included; 77.2% male, 52.6% Caucasian, 58.5% Eastern Cooperative Oncology Group performance status 0-1, 80.7% Child Pugh A. Treatment was second line and beyond in 71.9% of patients. The median follow-up time was 6 months. Sarcopenia cut-off for males and females was SMI of 43 and 39, respectively. 49.1% of patients had sarcopenia. Median OS was 5 versus 14.3 months in sarcopenic versus nonsarcopenic patients (Log-rank <jats:italic toggle=\"yes\">P<\/jats:italic>=0.054). Median OS was 5 and 17.5 months in patients with BMI &lt;25 and BMI \u226525, respectively (Log-rank <jats:italic toggle=\"yes\">P<\/jats:italic>=0.034). Median OS was 3.6 and 14.3 months for patients with neutrophil-to-lymphocyte ratio (NLR) \u22655.15 versus NLR &lt;5.15 (Log-rank <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). In multivariable Cox regression model, higher baseline NLR was associated with worse OS (hazard ratio [HR]: 4.17, 95% confidence interval [CI]: 1.52-11.39, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.005). Sex-specific sarcopenia showed a trend of worse OS (HR: 1.71, 95% CI: 0.73-4.00, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.215) but was not statistically significant. BMI&lt;25 was associated with worse OS (HR: 2.28, 95% CI: 0.92-5.65, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.076). In the association with progression free survival, neither baseline BMI nor sex-specific sarcopenia showed statistical significance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>After controlling for baseline Child Pugh score and NLR, sex-specific sarcopenia does not predict OS. Baseline BMI and NLR together may predict OS in advanced HCC patients treated with anti-PD-1 antibody.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000787","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T16:17:45Z","timestamp":1608567465000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":49,"title":["Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody"],"prefix":"10.1097","volume":"44","author":[{"given":"Mehmet","family":"Akce","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zakka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan J.","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Draper","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid L.","family":"Shaib","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel P.","family":"Wedd","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Digestive Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty T.","family":"Sellers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplantation, Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","article-title":"Molecular targeted therapies in hepatocellular carcinoma","volume":"48","author":"Llovet","year":"2008","journal-title":"Hepatology"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"e00058","DOI":"10.14309\/ctg.0000000000000058","article-title":"Immunologic features of patients with advanced hepatocellular carcinoma before and during sorafenib or anti-programmed death-1\/programmed death-L1 treatment","volume":"10","author":"Macek Jilkova","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncologist"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2019.11.011","article-title":"The impact of body mass index on the efficacy of anti-PD-1\/PD-L1 antibodies in patients with non-small cell lung cancer","volume":"139","author":"Ichihara","year":"2020","journal-title":"Lung Cancer"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.31778","article-title":"The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy","volume":"125","author":"Bilen","year":"2019","journal-title":"Cancer"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.aje.a009520","article-title":"Epidemiology of sarcopenia among the elderly in New Mexico","volume":"147","author":"Baumgartner","year":"1998","journal-title":"Am J Epidemiol"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"526.e9","DOI":"10.1016\/j.amjmed.2005.10.049","article-title":"Inflammatory markers and loss of muscle mass (sarcopenia) and strength","volume":"119","author":"Schaap","year":"2006","journal-title":"Am J Med"},{"key":"R17-20250527","first-page":"11","article-title":"Skeletal muscle: an endocrine organ","volume":"10","author":"Pratesi","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.2527\/jas.2007-0458","article-title":"Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition","volume":"86","author":"Quinn","year":"2008","journal-title":"J Anim Sci"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1759-7714.12965","article-title":"Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a \u201chypothesis-generator\u201d preliminary report","volume":"10","author":"Cortellini","year":"2019","journal-title":"Thorac Cancer"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","article-title":"Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography","volume":"85","author":"Mitsiopoulos","year":"1998","journal-title":"J Appl Physiol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.12688\/f1000research.16866.1","article-title":"Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS\u00ae macros","volume":"7","author":"Liu","year":"2018","journal-title":"F1000Res"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jclinepi.2016.03.031","article-title":"Regression coefficient-based scoring system should be used to assign weights to the risk index","volume":"79","author":"Mehta","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","article-title":"Immunosuppression associated with chronic inflammation in the tumor microenvironment","volume":"36","author":"Wang","year":"2015","journal-title":"Carcinogenesis"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt.15.126","article-title":"Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Hato","year":"2016","journal-title":"Immunotherapy"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.it.2017.05.008","article-title":"Molecular dissection of CD8(+) T-cell dysfunction","volume":"38","author":"Wang","year":"2017","journal-title":"Trends Immunol"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/rb\/rbw041","article-title":"An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration","volume":"4","author":"Selders","year":"2017","journal-title":"Regen Biomater"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"e172319","DOI":"10.1001\/jamaoncol.2017.2319","article-title":"Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study","volume":"3","author":"Feliciano","year":"2017","journal-title":"JAMA Oncol"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/jjco\/hyx103","article-title":"High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma","volume":"47","author":"Shao","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2017.02.128","article-title":"IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model","volume":"486","author":"Liu","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fimmu.2020.00245","article-title":"Obesity-associated alterations of natural killer cells and immunosurveillance of cancer","volume":"11","author":"B\u00e4hr","year":"2020","journal-title":"Front Immunol"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.pan.2016.09.007","article-title":"The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients","volume":"16","author":"Cheng","year":"2016","journal-title":"Pancreatology"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00520-015-2997-x","article-title":"Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer","volume":"24","author":"Go","year":"2016","journal-title":"Support Care Cancer"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5604\/16652681.1226821","article-title":"Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis","volume":"16","author":"Begini","year":"2017","journal-title":"Ann Hepatol"},{"key":"R38-20250527","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jamcollsurg.2010.03.039","article-title":"Sarcopenia and mortality after liver transplantation","volume":"211","author":"Englesbe","year":"2010","journal-title":"J Am Coll Surg"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1245\/s10434-014-3686-6","article-title":"Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma","volume":"21","author":"Itoh","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/bjs.9258","article-title":"Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma","volume":"100","author":"Harimoto","year":"2013","journal-title":"Br J Surg"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s12885-018-4673-2","article-title":"Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies","volume":"18","author":"Kobayashi","year":"2018","journal-title":"BMC Cancer"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","article-title":"Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma","volume":"7","author":"Mir","year":"2012","journal-title":"PLoS One"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3892\/ol.2017.6287","article-title":"Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy","volume":"14","author":"Nishikawa","year":"2017","journal-title":"Oncol Lett"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/2050640618781188","article-title":"Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment","volume":"6","author":"Antonelli","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000493586","article-title":"Body composition is an independent predictor of outcome in patients with hepatocellular carcinoma treated with sorafenib","volume":"8","author":"Labeur","year":"2019","journal-title":"Liver Cancer"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3892\/mco.2017.1321","article-title":"Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib","volume":"7","author":"Yamashima","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/hepr.12780","article-title":"Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib","volume":"47","author":"Hiraoka","year":"2017","journal-title":"Hepatol Res"},{"key":"R48-20250527","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/jcm8040450","article-title":"Association of sarcopenia with and efficacy of anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer","volume":"8","author":"Nishioka","year":"2019","journal-title":"J Clin Med"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.hpb.2017.04.008","article-title":"Prognostic value of combined preoperative prognostic nutritional index and body mass index in HCC after hepatectomy","volume":"19","author":"Ji","year":"2017","journal-title":"HPB (Oxford)"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.diii.2016.06.002","article-title":"Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization","volume":"98","author":"Wu","year":"2017","journal-title":"Diagn Interv Imaging"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00432-018-2610-z","article-title":"Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study","volume":"144","author":"Abdel-Rahman","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cam4.634","article-title":"Overweight and obesity predict better overall survival rates in cancer patients with distant metastases","volume":"5","author":"Tsang","year":"2016","journal-title":"Cancer Med"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10552-014-0435-x","article-title":"Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis","volume":"25","author":"Schlesinger","year":"2014","journal-title":"Cancer Causes Control"},{"key":"R56-20250527","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12416","article-title":"Obesity and cancer pathogenesis","volume":"1311","author":"Berger","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"R57-20250527","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-18-3661","article-title":"Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab","volume":"25","author":"De Giorgi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.jvir.2019.08.001","article-title":"Neutrophil\/lymphocyte ratio predicts increased risk of immediate progressive disease following chemoembolization of hepatocellular carcinoma","volume":"30","author":"Cruz","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"R59-20250527","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijsu.2018.05.022","article-title":"The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis","volume":"55","author":"Wang","year":"2018","journal-title":"Int J Surg"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/bmm-2017-0307","article-title":"The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis","volume":"12","author":"Xu","year":"2018","journal-title":"Biomark Med"},{"key":"R61-20250527","doi-asserted-by":"crossref","first-page":"103077","DOI":"10.18632\/oncotarget.21528","article-title":"Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib","volume":"8","author":"Lue","year":"2017","journal-title":"Oncotarget"},{"key":"R62-20250527","doi-asserted-by":"crossref","first-page":"67142","DOI":"10.18632\/oncotarget.11565","article-title":"Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib","volume":"7","author":"Casadei Gardini","year":"2016","journal-title":"Oncotarget"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00262-018-2126-z","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis","volume":"67","author":"Jiang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:12Z","timestamp":1748365692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000787","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}